Rapid Manufacture of Retroviral Vectors Encoding Tumor-Specific T Cell Receptors for Adoptive Cell Immunotherapy


Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and may serve as therapeutic targets. However, there are technical barriers making it difficult to engineer tumor-specific T cells unique to each patient. Thus, there is a need for new methods of producing these T cells in sufficient quantities to provide patients with adoptive cell immunotherapy.

Researchers at the National Cancer Institute (NCI) have developed a method that enables the GMP manufacture of gammaretroviral vectors encoding tumor mutation-specific T Cell receptors (TCRs) using transient transfection-based vector production methods. This approach encompasses the production of a fully validated 293GP master cell bank (MCB). The 293GP is a 293-based retroviral packaging cell line stably expressing the Moloney Murine Leukemia Virus gap-pol gene. This MCB has been biosafety tested to industry standards, including: testing for replication competent retrovirus (RCR), human viruses and other adventitious virus. This MCB will be used to produce a transient pMSGV1 gammaretrovirus encoding a TCR reactive to a patient-specific neoantigen. Vector supernatants will be manufactured for a single patient and used to transduce the patient's autologous peripheral blood lymphocytes; thereby generating a cell therapy product for use in a single patient.

The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate or commercialize this method of manufacturing vectors encoding cancer mutation-specific TCRs for adoptive cell immunotherapy.



Potential Commercial Applications: Competitive Advantages:
  • Personalized cell therapy targeting tumor specific mutations using gene modified T cells
  • High efficiency production of GMP-compliant viral vectors 
 
  • Method for generating autologous high frequency (up to 90%) tumor mutation-specific T-Cells directed against mutations expressed by the patient’s tumor


Development Stage:
Clinical

Related Invention(s):
E-233-2014


Inventors:

Steven Feldman (NCI)  ➽ more inventions...

Steven Rosenberg (NCI)  ➽ more inventions...


Intellectual Property:
Application No. 62/639,272

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-157-2017
Updated: Oct 15, 2018